Clinical Trial Update: Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating autologous genetically modified lymphocytes followed by Aldesleukin in patients with stage III or metastatic melanoma has completed, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Melanoma

Drugs mentioned

• Genetically Modified Therapeutic Autologous Lymphocytes
• Proleukin (aldesleukin)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7 | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-10-08